Importantly, no signs of severe systemic toxicity or cytokine release syndrome (CRS)—which has been documented in dogs treated with adoptive cell therapy and IL-2-based protocols (20, 21)—were observed in this study. The gene discussed is IL2; the disease is congenital rubella syndrome.